Lantheus Medical Imaging of North Billerica, MA, has launched its Ablavar injectable MR angiography (MRA) blood-pool imaging agent in Canada.
In Canada, Ablavar was previously marketed as Vasovist; it is used in contrast-enhanced MRA for visualizing abdominal or limb vessels in patients with suspected or known vascular disease. Earlier this year, Lantheus launched Ablavar in the U.S., where it is indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, according to Lantheus.
The launch is part of the company's strategy to expand its presence in international markets and to increase access to medically important diagnostic imaging agents, Lantheus said.
Related Reading
Lantheus to present cardiac PET data, September 20, 2010
Lantheus resumes TechneLite production, August 24, 2010
Lantheus launches Definity in India, July 15, 2010
Lantheus buys all Ablavar rights, July 12, 2010
Lantheus, MDS Nordion sign Mo-99 deal, July 8, 2010
Copyright © 2010 AuntMinnie.com
